证券代码：300254 证券简称：仟源医药 公告编号：2025-071 山西仟源医药集团股份有限公司 关于股东对外捐赠的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、捐赠事项概述 为支持南京大学教育事业发展，山西仟源医药集团股份有限公司（以下简称 "公司"、"仟源医药"）董事长、股东黄乐群先生拟与南京大学教育发展基金 会（以下简称"南大基金会"）签署《捐赠协议书》，黄乐群先生拟向南大基金 会无偿捐赠20万股，占截至本公告日公司总股本的0.08%。本次捐赠的股份来源 于二级市场增持的股份，且均为无限售流通股。同时，黄乐群先生的一致行动人 赵群先生持股15,781,792股，占公司总股本的6.16%，黄乐群先生及其一致行动 人赵群先生合计持股21,246,852股，占公司总股本的8.29%。本次捐赠事宜不会导 致公司股权分布不符合上市条件，公司第一大股东仍为赵群先生及其一致行动人 黄乐群先生，公司仍无实际控制人和控股股东，不会导致公司实际控制人及控股 股东发生变化。 公司及股东黄乐群先生与南大基金会不存在关联关系，本次签署《捐赠协议》 不构成关联交易。 ...

证券代码：300254 证券简称：仟源医药 公告编号：2025-070 山西仟源医药集团股份有限公司 2025年第三季度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 10 月 29 日，山西仟源医药集团股份有限公司（以下简称"公司"） 召开了第五届董事会第三十五次会议，审议通过了《关于公司<2025 年第三季度 报告>的议案》。 为使投资者全面了解公司的经营成果、财务状况,公司《2025 年第三季度报 告》于 2025 年 10 月 30 日在中国证监会指定的创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）披露，敬请广大投资者注意查阅。 特此公告 山西仟源医药集团股份有限公司 董事会 二○二五年十月三十日 ...

Group 1 - The core viewpoint of the article highlights that Q3 revenue for QianYuan Pharmaceutical reached 238 million yuan, representing a year-on-year increase of 14.82% [1] - The net profit for Q3 was 21.9466 million yuan, showing a significant year-on-year growth of 106.06% [1] - For the first three quarters, the total revenue amounted to 611 million yuan, which is a slight year-on-year increase of 0.44% [1] Group 2 - The net profit for the first three quarters was 22.3274 million yuan, indicating a year-on-year decline of 49.43% [1]

Financial Performance - The company's operating revenue for Q3 2025 reached ¥238,477,452.79, representing a year-on-year increase of 14.82%[5] - Net profit attributable to shareholders was ¥21,946,557.84, a significant increase of 106.06% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥22,538,701.88, up 212.36% year-on-year[5] - The total operating revenue for the current period is ¥611,473,385.33, slightly up from ¥608,815,610.55 in the previous period, indicating a growth of approximately 0.27%[23] - Net profit for the current period was ¥48,470,797.18, down from ¥67,158,532.63, representing a decline of about 28%[25] - The total profit increased to ¥77,369,333.81 from ¥73,407,341.08, an increase of approximately 4.1%[24] - Basic earnings per share decreased to ¥0.0922 from ¥0.1827, a decline of about 49%[25] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥1,549,765,358.12, reflecting a slight increase of 0.13% from the end of the previous year[5] - Total assets amounted to ¥1,549,765,358.12, a slight increase from ¥1,547,725,078.17, indicating a growth of approximately 0.07%[21] - Total liabilities increased to ¥972,673,007.61 from ¥949,545,094.09, representing a rise of about 2.42%[21] - The company's equity attributable to shareholders decreased to ¥294,207,395.41 from ¥342,998,882.45, a decline of approximately 14.26%[21] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥75,411,853.86, an increase of 19.56% compared to the previous year[9] - Operating cash flow net amount increased to ¥75,411,853.86 from ¥63,071,990.33, an increase of approximately 19%[28] - Cash and cash equivalents decreased to ¥128,975,832.88 from ¥149,518,040.96, representing a decline of about 13.73%[19] - Cash and cash equivalents at the end of the period decreased to ¥128,964,832.88 from ¥176,467,322.01, a decline of about 27%[29] - Investment activities resulted in a net cash flow of -¥88,810,515.70, worsening from -¥59,371,258.67[28] - Financing activities generated a net cash flow of -¥7,143,546.24, compared to a positive cash flow of ¥40,774,022.37 in the previous period[29] Shareholder Information - The total number of common shareholders at the end of the reporting period is 24,916[11] - The top 10 shareholders hold a total of 56,000,000 shares, with Zhao Qun and Huang Lequn each holding 6.16% of the shares[11] - Zhao Qun has 15,781,792 shares, of which 11,836,344 are subject to lock-up restrictions[13] - The total number of restricted shares at the end of the reporting period is 30,424,393, with 9,439,925 shares added during the period[14] - The company has a stock incentive plan that allows for 25% of restricted shares to be unlocked annually starting in 2024[13] - The company held a board meeting to approve the 2025 stock incentive plan and related amendments[15] - The company has 204 core technical and key personnel with a total of 10,400,000 restricted shares under the incentive plan[14] - The top shareholder, Zhao Qun, has a total of 10,276,419 restricted shares at the beginning of the period[13] - The company has not disclosed any related party relationships among the top shareholders[11] Expenses and Costs - Financial expenses for the year-to-date were ¥17,522,800.00, an increase of 50.80% compared to the same period last year, mainly due to higher bank loan interest[9] - The company reported a decrease in other income by 62.88% year-on-year, amounting to ¥3,433,400.00, primarily due to reduced government subsidies received[9] - Total operating costs decreased from ¥563,187,725.70 to ¥552,167,468.27, a reduction of approximately 1.8%[24] - The company reported a tax expense of ¥28,898,536.63, significantly higher than ¥6,248,808.45 in the previous period[24] Other Information - The balance of construction in progress increased by 149.71% year-on-year, reaching ¥38,165,100.00, due to new factory renovation projects[8] - The balance of prepaid expenses increased by 51.33% year-on-year, totaling ¥4,323,600.00, primarily due to increased advance payments for goods[8] - The company's independent director Gao Hao resigned during the reporting period[15]

Group 1 - QianYuan Pharmaceutical (300254.SZ) experienced a decline of 3.91% in intraday trading, reaching a price of 10.57 yuan [2] - The company announced that a shareholder holding more than 5% of shares, Weng Zhangguo, plans to reduce his holdings by up to 7.6831 million shares, which represents no more than 3% of the company's total share capital [2]

Core Viewpoint - The shareholder Weng Zhangguo of Qianyuan Pharmaceutical plans to reduce his stake in the company by up to 7.6831 million shares, representing no more than 3% of the total share capital, through centralized bidding and block trading from November 13, 2025, to February 12, 2026 [1] Summary by Relevant Sections - Shareholder Reduction Plan - Weng Zhangguo intends to reduce his holdings by a maximum of 7.6831 million shares [1] - This reduction will account for up to 3% of the company's total share capital [1] - The planned timeframe for this reduction is from November 13, 2025, to February 12, 2026 [1]

Group 1 - On October 22, no A-share listed companies disclosed any increase in shareholding [1] - A total of 10 A-share listed companies announced share reductions, including Tai Lingwei, Jindan Technology, Shenlian Biology, Qianyuan Pharmaceutical, Hengsheng Energy, Zhengfan Technology, Lanshi Heavy Industry, Haiguo Co., Ganfeng Lithium, and Hengsuo Co. [1] Group 2 - Tai Lingwei's second largest shareholder, the National Big Fund, plans to reduce its stake by no more than 2% [2] - Jindan Technology's shareholder, Guangzhou Chengxin, intends to reduce its stake by no more than 1.05% [2] - Shenlian Biology's shareholder, UB, plans to reduce its stake by no more than 3% [2] - Qianyuan Pharmaceutical's shareholder, Weng Zhangguo, intends to reduce its stake by no more than 3% [2] - Zhengfan Technology's directors and supervisors plan to collectively reduce their stake by no more than 1.88% [2] - Hengsheng Energy's actual controller has already reduced his stake by 501,600 shares [2] - Lanshi Heavy Industry's shareholder, Hualing Xianggang, plans to reduce its stake by no more than 1% [2] - Haiguo Co.'s shareholder, Yujian Chuangtou, intends to reduce its stake by no more than 0.9965% [2] - Ganfeng Lithium's vice president, Fu Lihua, plans to reduce his stake by no more than 40,000 shares [2] - Hengsuo Co.'s shareholders collectively plan to reduce their stake by no more than 3% [2]

Core Viewpoint - The article summarizes significant announcements from various listed companies in the Shanghai and Shenzhen stock markets, highlighting potential investment opportunities and risks based on recent developments and financial performance. Group 1: Company Announcements - Tianpu Co., Ltd. warns that its stock price has significantly deviated from its fundamentals, with a cumulative increase of 246.02% from August 22 to October 22, indicating a potential for rapid decline [4] - Shenzhen Sanda A plans to sell stakes in several subsidiaries to focus on its core business, including 80% of Zhongdian Continental Environmental Technology [5][6] - Zhongchong Co., Ltd. received an administrative regulatory measure from the Shandong Securities Regulatory Bureau for failing to announce a significant change in shareholding [7] - Construction Machinery has reported a net loss of 447 million yuan for the first half of 2025, marking three consecutive years of losses [8] - Junshi Biosciences announced that its subsidiary passed a recent FDA inspection, indicating compliance with CGMP standards [9] Group 2: Financial Performance - Duofuduo reported a net profit increase of 407.74% year-on-year for the first three quarters of 2025, with a revenue of 6.73 billion yuan [17] - Weihuaxincai achieved a net profit growth of 250.04% year-on-year in Q3, with revenues of 660 million yuan [18] - Guangdong Jianke reported a net profit increase of 190.62% year-on-year for the first three quarters, despite a revenue decline [19] - Xianggang Technology reported a net profit increase of 186.19% year-on-year for the first three quarters, with revenues of 742 million yuan [20] - Defu Technology reported a net profit increase of 132.63% year-on-year for the first three quarters, driven by increased copper foil sales [21] Group 3: Major Transactions and Investments - Tangrenshen plans to establish two investment funds with a total investment of 11.04 million yuan to focus on the agricultural sector [13] - Farsen intends to sell a 10% stake in Bekaert Steel Cord, constituting a major asset restructuring [14] - Shikong Technology plans to acquire 100% of Jiahe Jingwei, entering the storage sector [15] - Jiangsu New Energy's controlling shareholder is investing in offshore wind power projects and will manage the project companies [11][12] Group 4: Shareholder Actions - Qianyuan Pharmaceutical's shareholder plans to reduce its stake by up to 3% [42] - Zhengfan Technology's board members plan to collectively reduce their holdings by up to 1.88% [43]

Core Viewpoint - The shareholder Weng Zhangguo of Qianyuan Pharmaceutical (300254.SZ) plans to reduce his stake in the company by up to 7.6831 million shares, representing no more than 3% of the total share capital, through centralized bidding and block trading from November 13, 2025, to February 12, 2026 [1] Summary by Category - **Shareholder Actions** - Weng Zhangguo intends to reduce his holdings in Qianyuan Pharmaceutical by a maximum of 7.6831 million shares [1] - The planned reduction accounts for up to 3% of the company's total share capital [1] - **Timeline** - The reduction is scheduled to take place between November 13, 2025, and February 12, 2026 [1] - **Method of Reduction** - The shares will be sold through centralized bidding and block trading methods [1]

北京商报讯（记者 丁宁）10月22日晚间，仟源医药（300254）发布公告称，公司于近日收到持股5%以 上股东翁占国出具的《关于股份减持计划的告知函》，其计划自公告披露之日起15个交易日后的3个月 内以集中竞价和大宗交易的方式减持公司股份不超过768.31万股（占公司总股本比例不超过3%）。 公告显示，翁占国持有公司股份1577.24万股，占公司总股本的6.16%。 ...